bioMérieux (BIM) 44th Annual J.P. Morgan Healthcare Conference 2025 presentation summary

Company profile and market position

• Achieved €4bn in 2024 revenues, a 50% increase since 2019, with strong geographic and business diversification.

• Holds leading positions: #1 in Highplex Molecular and Microbiology, #2 in Industrial Applications.

• 82% of revenues are recurring, with 12% of sales invested in R&D to drive innovation.

• 85% of sales come from clinical diagnostics, mainly infectious disease and antibiotic susceptibility testing.

Strategic plan and financial targets (GO.28)

• GO.28 aims for +7% CAGR sales growth from 2024 to 2028, with a focus on profitable, sustainable growth.

• 2024 sales reached €4bn (+10% vs 2023), with CEBIT2 at €673m (+20% vs 2023).

• 2025 guidance targets 5.5%–6.5% sales growth and 12%–18% CEBIT2 growth vs 2024.

• Committed to a 50% reduction in GHG emissions by 2030 (Scope 1 & 2).

Growth drivers

• Four main growth drivers: BIOFIRE® Non-Respiratory Panels (+10% CAGR), SPOTFIRE® PoC platform (targeting €450m by 2028), Microbiology (+6–8% CAGR), and Industrial Applications (+7–9% CAGR).

• BIOFIRE® Non-Respiratory Panels hold ~75% market share with the largest installed base and rapid results.

• SPOTFIRE® has achieved a 5%+ PoC market share within two years, with rapid menu expansion and international growth.

• Microbiology growth is driven by antimicrobial resistance trends and ongoing innovation in instruments and reagents.

• Industrial Applications benefit from regulatory trends and innovation in risk detection and prevention.